Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Lancet Haematol. 2022 Mar 25;9(5):e340–e349. doi: 10.1016/S2352-3026(22)00069-2

Figure 2. Description of all monoclonal gammopathies detected in our study cohort.

Figure 2.

Figure 2.

(A) Prevalence of MGs by age binned in 2-year intervals, modeled by local regression with 95% confidence intervals reported. (Left) Prevalence of MS-MGUS only. (Right) Prevalence of MS-MGUS and MGIP. (B) Left to right: Prevalence of all three sub-types of MGs by age, gender, and MM risk group.